CARGO THERAPEUTICS INC (CRGX)

US14179K1016 - Common Stock

15.94  +0.12 (+0.76%)

Fundamental Rating

3

CRGX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 565 industry peers in the Biotechnology industry. CRGX has a great financial health rating, but its profitability evaluates not so good. CRGX does not seem to be growing, but still is valued expensively.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

CRGX had negative earnings in the past year.
In the past year CRGX has reported a negative cash flow from operations.

1.2 Ratios

CRGX has a better Return On Assets (-30.14%) than 67.38% of its industry peers.
CRGX has a better Return On Equity (-33.87%) than 77.36% of its industry peers.
Industry RankSector Rank
ROA -30.14%
ROE -33.87%
ROIC N/A
ROA(3y)-183.86%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CRGX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, CRGX has more shares outstanding
CRGX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

CRGX has an Altman-Z score of 7.43. This indicates that CRGX is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of CRGX (7.43) is better than 83.78% of its industry peers.
There is no outstanding debt for CRGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.43
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 16.96 indicates that CRGX has no problem at all paying its short term obligations.
CRGX has a Current ratio of 16.96. This is amongst the best in the industry. CRGX outperforms 91.27% of its industry peers.
A Quick Ratio of 16.96 indicates that CRGX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 16.96, CRGX belongs to the top of the industry, outperforming 91.27% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 16.96
Quick Ratio 16.96

More info and screens

1

3. Growth

3.1 Past

CRGX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -124.71%.
EPS 1Y (TTM)-124.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-29.31%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

CRGX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.04% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y81.02%
EPS Next 2Y33.89%
EPS Next 3Y22.04%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CRGX. In the last year negative earnings were reported.
Also next year CRGX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as CRGX's earnings are expected to grow with 22.04% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.89%
EPS Next 3Y22.04%

More info and screens

0

5. Dividend

5.1 Amount

CRGX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CARGO THERAPEUTICS INC

NASDAQ:CRGX (11/21/2024, 2:27:37 PM)

15.94

+0.12 (+0.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap731.65M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -30.14%
ROE -33.87%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 16.96
Quick Ratio 16.96
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-124.71%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y81.02%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y